-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nilotinib in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nilotinib in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nilotinib in Parkinson's Disease Drug Details: Nilotinib is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRX-3140 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRX-3140 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRX-3140 in Alzheimer's Disease Drug Details:PRX-03140 (NTC-942) is under development for the treatment of Alzheimer's...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Colestilan Chloride in Familial Amyloid Neuropathies
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Colestilan Chloride in Familial Amyloid Neuropathies report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Colestilan Chloride in Familial Amyloid Neuropathies Drug Details: Colestilan chloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SNK-01 in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNK-01 in Leiomyosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SNK-01 in Leiomyosarcoma Drug Details:SNK-01 is under development for the treatment of Alzheimer's disease,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAGE-718 in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SAGE-718 in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UE-2343 in Alzheimer’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. UE-2343 in Alzheimer's Disease Drug Details: UE-2343 (Xanamem) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAGE-718 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SAGE-718 in Parkinson's Disease report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UE-2343 in Major Depressive Disorder
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.UE-2343 in Major Depressive Disorder Drug Details: UE-2343 (Xanamem) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Colestilan Chloride in Functional (Non Ulcer) Dyspepsia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Colestilan Chloride in Functional (Non Ulcer) Dyspepsia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Colestilan Chloride in Functional (Non Ulcer) DyspepsiaDrug Details: Colestilan chloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalzanemdor in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalzanemdor in Mild Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dalzanemdor in Mild Cognitive ImpairmentDrug Details:Dalzanemdor (SAGE-718) is under development for the...